These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34086100)

  • 1. Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease.
    Rompicherla SKL; Arumugam K; Bojja SL; Kumar N; Rao CM
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1737-1755. PubMed ID: 34086100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting.
    Shah B; Khunt D; Misra M; Padh H
    Pharm Res; 2018 Jan; 35(1):8. PubMed ID: 29294189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization.
    Shah BM; Misra M; Shishoo CJ; Padh H
    Drug Deliv; 2015; 22(7):918-30. PubMed ID: 24467601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral and Biochemical Implications of Dendrimeric Rivastigmine in Memory-Deficit and Alzheimer's Induced Rodents.
    Gothwal A; Singh H; Jain SK; Dutta A; Borah A; Gupta U
    ACS Chem Neurosci; 2019 Aug; 10(8):3789-3795. PubMed ID: 31257860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice.
    Sunena ; Singh SK; Mishra DN
    Curr Drug Deliv; 2019; 16(1):51-58. PubMed ID: 30289074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, development and in-vitro/in-vivo evaluation of intranasally delivered Rivastigmine and N-Acetyl Cysteine loaded bifunctional niosomes for applications in combinative treatment of Alzheimer's disease.
    Kulkarni P; Rawtani D; Barot T
    Eur J Pharm Biopharm; 2021 Jun; 163():1-15. PubMed ID: 33774160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinergic Modification of Neurogenesis and Gliosis Improves the Memory of AβPPswe/PSEN1dE9 Alzheimer's Disease Model Mice Fed a High-Fat Diet.
    Matsuda T; Hisatsune T
    J Alzheimers Dis; 2017; 56(1):1-23. PubMed ID: 27911310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease.
    Ismail MF; Elmeshad AN; Salem NA
    Int J Nanomedicine; 2013; 8():393-406. PubMed ID: 23378761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DL0410, a novel dual cholinesterase inhibitor, protects mouse brains against Aβ-induced neuronal damage via the Akt/JNK signaling pathway.
    Zhou D; Zhou W; Song JK; Feng ZY; Yang RY; Wu S; Wang L; Liu AL; Du GH
    Acta Pharmacol Sin; 2016 Nov; 37(11):1401-1412. PubMed ID: 27498773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats.
    Gawel K; Labuz K; Gibula-Bruzda E; Jenda M; Marszalek-Grabska M; Filarowska J; Silberring J; Kotlinska JH
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1059-71. PubMed ID: 27376896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Development of Novel Transdermal Nanoemulgel for Alzheimer's Disease: Pharmacokinetic, Pharmacodynamic and Biochemical Investigations.
    Setya S; Madaan T; Razdan BK; Farswan M; Talegaonkar S
    Curr Drug Deliv; 2019; 16(10):902-912. PubMed ID: 31642410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revalidation of the neuroprotective effects of a United States patented polyherbal formulation on scopolamine induced learning and memory impairment in rats.
    Upadhyay P; Sadhu A; Singh PK; Agrawal A; Ilango K; Purohit S; Dubey GP
    Biomed Pharmacother; 2018 Jan; 97():1046-1052. PubMed ID: 29136783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic development of lectin conjugated microspheres for nose-to-brain delivery of rivastigmine for the treatment of Alzheimer's disease.
    Gao Y; Almalki WH; Afzal O; Panda SK; Kazmi I; Alrobaian M; Katouah HA; Altamimi ASA; Al-Abbasi FA; Alshehri S; Soni K; Ibrahim IAA; Rahman M; Beg S
    Biomed Pharmacother; 2021 Sep; 141():111829. PubMed ID: 34147904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration.
    Yang ZZ; Zhang YQ; Wang ZZ; Wu K; Lou JN; Qi XR
    Int J Pharm; 2013 Aug; 452(1-2):344-54. PubMed ID: 23680731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rivastigmine on scopolamine-induced memory impairment in rats.
    Bejar C; Wang RH; Weinstock M
    Eur J Pharmacol; 1999 Nov; 383(3):231-40. PubMed ID: 10594314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
    Polinsky RJ
    Clin Ther; 1998; 20(4):634-47. PubMed ID: 9737824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of rivastigmine liposomes for delivery into the brain through intranasal route.
    Arumugam K; Subramanian GS; Mallayasamy SR; Averineni RK; Reddy MS; Udupa N
    Acta Pharm; 2008 Sep; 58(3):287-97. PubMed ID: 19103565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic Modeling to Simulate the Concentration-Time Profiles After Dermal Application of Rivastigmine Patch.
    Nozaki S; Yamaguchi M; Lefèvre G
    J Pharm Sci; 2016 Jul; 105(7):2213-21. PubMed ID: 27212635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.
    Gobburu JV; Tammara V; Lesko L; Jhee SS; Sramek JJ; Cutler NR; Yuan R
    J Clin Pharmacol; 2001 Oct; 41(10):1082-90. PubMed ID: 11583476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naproxen as a potential candidate for promoting rivastigmine anti-Alzheimer activity against aluminum chloride-prompted Alzheimer's-like disease in rats; neurogenesis and apoptosis modulation as a possible underlying mechanism.
    Abdel-Aal RA; Hussein OA; Elsaady RG; Abdelzaher LA
    Eur J Pharmacol; 2022 Jan; 915():174695. PubMed ID: 34914971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.